Sagimet Biosciences prices $115 million offering of Series A shares and pre-funded warrants

SGMT•2026-09-30

Sagimet Biosciences priced an underwritten offering totaling $115 million, including 8.8 million Series A common shares at $10 per share.

1. Offering pricing

Sagimet Biosciences announced pricing of a $115 million underwritten offering of Series A common stock and pre-funded warrants. The company priced 8.8 million Series A common shares at $10 per share.

Sagimet Biosciences prices $115 million offering of Series A shares and pre-funded warrants

1. Offering pricing

Related News

Aqua Pennsylvania acquires Ulster Municipal Authority water system in Bradford County

Nasdaq grants Evogene additional 180-day extension to regain $1 minimum bid compliance

Ocugen to present 12-month Phase 2 ArMaDa trial results for OCU410 gene therapy in geographic atrophy at AAO 2026

CytoSorbents flags new CytoSorb clinical data presentations at EACTS, ESICM conferences

FactSet Q4 revenue slightly beats on high annual subscription retention rates